Stockreport

Denosumab Biosimilar Launch in Europe Could Be A Game Changer For Sandoz Group (SWX:SDZ) [Yahoo! Finance]

Evotec SE  (EVO) 
NASDAQ:AMEX Investor Relations: eatonvance.com
PDF Xgeva® and Prolia® indications, targeting cancer-related bone disease and osteoporosis. This move expands Sandoz's presence in a roughly US$6.60 billion reference-medi [Read more]